Literature DB >> 35730882

INFLAMMATORY BOWEL DISEASES: CHARACTERISTICS, EVOLUTION, AND QUALITY OF LIFE.

Caique Moraes Mendonça1, Isaac José Felippe Correa Neto2, Alexander de Sá Rolim2, Laercio Robles2.   

Abstract

AIM: Inflammatory bowel diseases present progressive and potentially debilitating characteristics with an impact on health-related quality of life (QoL) throughout the course of the disease, and this parameter may even be used as a method of evaluating response to treatment. The aim of this study was to analyze epidemiological data, medications in use, previous surgeries, and hospitalizations in patients with inflammatory bowel diseases, and to determine the impairment in QoL of these patients.
METHODS: This is a prospective, cross-sectional, observational study in patients with inflammatory bowel disease followed up in a tertiary hospital in São Paulo-SP, Brazil. General and disease-related, evolution, and quality-of-life data were analyzed using a validated quality-of-life questionnaire, namely, Inflammatory Bowel Disease Questionnaire (IBDQ).
RESULTS: Fifty-six individuals were evaluated, with an equal number of patients with Crohn's disease and ulcerative colitis. A higher prevalence of previous surgeries (p=0.001) and hospitalizations (p=0.003) for clinical-surgical complications was observed in patients with Crohn's disease. In addition, the impairment of QoL also occurred more significantly in these patients (p=0.022), and there was a greater impact on females in both forms of inflammatory bowel disease (p=0.005).
CONCLUSIONS: Patients with Crohn's disease are more commonly submitted to surgeries and hospitalizations. Patients affected by both forms of inflammatory bowel disease present impairments in QoL, which are mainly related to intestinal symptoms, and females are more affected than men.

Entities:  

Mesh:

Year:  2022        PMID: 35730882      PMCID: PMC9254613          DOI: 10.1590/0102-672020210002e1653

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


INTRODUCTION

Inflammatory bowel disease (IBD) refers to a group of diseases [Crohn’s disease (CD) and ulcerative colitis (UC)] that are autoimmune, chronic, and of unknown etiology , . Moreover, it presents progressive and potentially debilitating characteristics . The study of health-related quality of life (HRQoL) in these patients is relevant, as it can lead to changes in the social, psychological, and social-professional spheres and, during the course of the disease, several factors that interact and combine can cause different impacts on the degree of life satisfaction of these individuals and can even be used as a method to evaluate the treatment , . Symptoms such as profuse chronic diarrhea, abdominal pain, and hyporexia affect HRQoL. Therapeutic measures, whether conservative (adverse drug effects) or surgical (resections, definitive ostomies) , result in frequent adverse effects in the long term , , affecting the life of patient mentally, emotionally, physiologically, socially, and physically . The objective was to cross-sectionally analyze epidemiological data, medications in use, previous surgeries, and hospitalizations in patients with IBDs at the Coloproctology Unit of the Department of General Surgery of Santa Marcelina Hospital and determine the impairment of QoL of these patients and the aspects involved in this impairment.

METHODS

This is a prospective, cross-sectional, observational study involving patients with IBD (CD and UC) followed at the Coloproctology Unit of the Department of General Surgery of Santa Marcelina Hospital, from March 2019 to February 2020. Patients over 18 years of age, with physical and mental capacity to participate in the study and agree with the term of consent and participation in the work, were included. Pregnant women and patients with an indication for emergency hospitalization were excluded. The following items were analyzed: General data: age, sex, race, marital status, education, body mass index (BMI), smoking, and comorbidities Disease-related data: length of disease, previous hospitalization due to clinical and/or surgical complications, and medications in use Application of IBD Life Questionnaire: IBDQ (Intestinal Bowel Disease Questionnaire) , , , , , , , , , which contains 32 items comprising four domains: Intestinal symptoms (10 questions - 01, 05, 09, 13, 17, 20, 22, 24, 26, 29; ranging from 10 to 70 points): frequency of bowel movements; diarrhea; abdominal cramping; discomfort from pain in the belly; problem with eliminating large amounts of gas; feeling of bloating in the belly; rectal bleeding on bowel movements; discomfort from going to the toilet to evacuate and not being able to despite effort and from accidentally evacuating in the pants; feeling of nausea Systemic symptoms (five questions - 02, 06, 10, 14, 18; ranging from 5 to 35 points): feeling of tiredness, fatigue, exhaustion; physical tiredness; feeling of malaise; sleep disturbance because of intestinal problem; problem to maintain weight as you would like it to be Emotional aspects (12 questions - 03, 07, 11, 15, 19, 12, 23, 25, 27, 30, 31, 32; ranging from 12 to 84 points): frequency of feeling frustrated, impatient, or restless; worried about the possibility of needing an operation for the bowel problem; frequency that one has felt depressed and lacking courage; frequency that one feels worried or anxious; how long one has felt calm and relaxed; embarrassment because of the bowel problem; urge to cry; anger over the bowel problem; how long one has felt angry; lack of understanding from other people; how satisfied, happy, or grateful one feels about their personal life. Social aspects (five questions - 04, 08, 12, 16, 28; ranging from 5 to 35 points): inability to go to school or work because of the bowel problem; need to delay or cancel social engagements; difficulty doing sports or having fun as one would like to because of the bowel problem; avoid going to places that do not have toilets nearby; avoid sexual activity because of the bowel problem. The score of the answers was presented through multiple choice with seven alternatives (Likert scale), with each question ranging from 1 (representing a “worst” aspect) to 7 (representing a “best” aspect), so that the total IBDQ score is between 32 and 224; the lower the score, the greater the impact on QoL , , . The author provided the informed consent form and then the questionnaire to the participant. If the participant had any doubts, the interviewer repeated the wording of each question to reinforce the understanding of the interviewee. The study was evaluated and approved by the Faculty of Medicine Santa Marcelina’s Research Orientation Committee (COPE-FASM: opinion number P010/2019), by Plataforma Brasil, and the consubstantiated opinion of the ROC (number: 3.574.576). Statistical analyses were performed using the IBM SPSS Statistics version 20 software for Windows, and Pearson’s correlation analysis was used with a power of 95% and alpha probability fixed at 5%. The scatter diagram was used to verify the relationship between various aspects and total score. The differences between the total IBDQ of comparative groups of CD and UC were combined using the Student’s t-test. The verification of homogeneity or heterogeneity of variances was carried out by one-tailed F test. For the stratification of data related to sex, the dummy binary variable was created. The dispersion diagram with the curve plot for a trend line and ANOVA was used to indicate which of the symptoms best fit the IBDQ score (Crohn’s alpha coefficient for intestinal, systemic, emotional, social, and total with 95%), and for all analyses, a value of p=0.05 was considered.

RESULTS

Fifty-six patients with IBD were evaluated, with equal number of patients with CD and UC, and the demographic characteristics are summarized in Table 1.
Table 1 -

General data on the prevalence of IBD, CD, and UC regarding marital status, education, gender, color, smoking, comorbidities, duration of disease, BMI, and age of the patients.

CharacteristicsIBD (%)CD (%)UC (%)
Sample56 (100%)28 (50%)28 (50%)
Marital status
Single23 (41.07%)13 (46.42%)10 (35.71%)
Married25 (44.6%)13 (46.42%)12 (42.85%)
Divorced3 (5.35%)0 (0%)3 (10.71%)
Widower5 (8.9%)2 (7.14%)3 (10.71%)
Education
Less or equal to primary education17 (30.35%)7 (25%)10 (35.7%)
Less or equal to secondary education25 (44.64%)13 (46.5%)12 (42.85%)
Less or equal to undergraduate degree14 (25%)8 (28.5%)6 (21.4%)
Gender
Male26 (46.4%)11 (39.3%)15 (53.6%)
Female30 (53.6%)17 (60.7%)13 (46.4%)
Race
Caucasian34 (60.7%)16 (57.1%)18 (64.3%)
African-American7 (12.5%)2 (7.1%)5 (17.9%)
Brown15(26.7%)10 (35.7%)5 (17.9%)
BMI (kg/m2): Average ± SD25,7 ± 4,9824,59 ± 5,0326,85 ± 4,76
Age (years): Average ± SD45.93 ± 17.541.21 ± 15.8550.64 ± 18.1
Smoking
Yes3 (5.4%)0 (0%)3 (10.7%)
No53 (94.6)28 (100%)25 (89.3%)
Comorbities
No32 (57.1%)18 (64.3%)14 (50%)
Yes24 (42.9%)10 (35.7%)14 (50%)
Figure 1 shows the prevalence of IBD and of the CD and UC forms in relation to the time of disease, where it can be seen that in most of the study patients the prevalence of disease was found between 1 and 10 years.
Figure 1 -

Prevalence of IBD and CD and UC forms in relation to the time of disease.

Regarding previous surgeries, we observed that 23 patients with IBD (41.1%) had undergone some surgical procedures, mostly intestinal. Of the patients with CD, 67.9% had already undergone surgery, whereas among the patients with UC, only 14.2% had undergone surgery (p=0.001) (Table 1). Notably, 27 (48.2%) patients with IBD, 19 (67.9%) patients with CD, and 8 (28.6%) patients with UC (p=0.003) required hospitalization for clinical-surgical complications(Table 2).
Table 2 -

Prevalence data of CD and UC regarding previous surgeries and hospitalization for clinical-surgical complication.

CharacteristicIBD (%)CD (%)UC (%)
Previous surgeries
No33 (58.9%)9 (32.1%)24 (85.7%)
Colorectal15 (26.8%)13 (46.1%)2 (7.1%)
Colorectal and orificial1 (1.8%)1 (3.6%)0 (0%)
Orificial7 (12.5%)5 (17.9%)2 (7.1%)
Hospitalization for clinical-surgical complication
Yes27 (48.2%)19 (67.9%)8 (28.6%)
No29 (51.8%)9 (32.1%)20 (71.4%)
Table 3 stratifies the surgeries according to the length of disease, where it is possible to verify that most surgical procedures occurred in both diseases between 5 and 10 years of diagnosis, notably in patients with CD (p=0.003).
Table 3 -

Prevalence of previous surgeries in relation to the length of disease.

Previous surgeries and duration of disease
Length of diseasePrevious surgeries
Number (%)Colorectal (%) Colorectal orificial (%)Orificial (%)
IBD
Up to 4 years8 (24.2%)6 (40%)0 (0%)4 (57.1%)
5-10 years18 (54.5%)5 (33.3%)0 (0%)3 (42.9%)
>10 years7 (21.2%)4 (26.7%)1 (100%)0 (0%)
Total33 (100%)15 (100.0%)1 (100%)7 (100%)
CD
Up to 4 years2 (22.2%)5 (38.5%)0 (0%)3 (60%)
5-10 years5 (55.6%)4 (30.8%)0 (0%)2 (40%)
>10 years2 (22.2%)4 (30.8%)1 (100%)0 (0%)
Total9 (100%)13 (100%)1 (100%)5 (100%)
UC
Up to 4 years2 (22.2%)5 (38.5%)0 (0%)3 (60%)
5-10 years5 (55.6%)4 (30.8%)0 (0%)2 (40%)
>10 years2 (22.2%)4 (30.8%)1 (100%)0 (0%)
Total9 (100%)13 (100%)1 (100%)5 (100%)
Regarding pharmacological therapy, the following drugs are used: aminosalicylates in 27 (48.2%), 5 (17.9%), and 22 (78.6%) patients with IBD, corticosteroids in 9 (16.1%), 5 (16.9%), and 4 (14.3%) patients with CD, immunosuppressants in 13 (23.2%), 11 (39.3%), and 2 (7.1%) patients with UC, and immunobiologicals in 25 (44.6%), 22 (78.6%), and 3 (10.7%) patients. Table 4 presents the results of analysis of the IBDQ domains in IBD, CD, and UC using Student’s t-test, where one can observe a higher index of global, bowel, and systemic symptoms in UC, and thus a lower impact on QoL of patients (p=0.022).
Table 4 -

Domains of the global IBDQ in IBD, CD, and UC

IBDQ ScoreIBD (n=56)CD (n=28)UC (n=28)p-value
Intestinal symptoms52.39±14.05 49.21±16.6955.57±10.130.045
Systemic symptoms23.84±8.5421.11±9.5026.57±6.550.007
Emotional aspects56.00±19.5452.82±21.3360.85±17.000.060
Social aspects24,55±9,0522.00±9.7727.10±7.600.016
Total IBDQ 157.63±46.67145.14±52.77170.1±36.470.022
Table 5 stratifies the values of IBDQ questionnaire in IBD, CD, and UC and correlates them with gender using Student’s t-test, where we observed a higher score in males. Table 6 stratifies the domains in CD and UC and shows comparison between genders.
Table 5 -

IBDQ index score in IBD, CD, and UC comparing genders

ScoreAverage + SD
Total IBDQIBDp-value
178.54±37.72139.51±46.610.0005
CDp-value
175.82±44.13125.29±49.150.004
UCp-value
180.53±33.76158.08±37.020.05
Table 6 -

Stratification of IBDQ domains in CD and UC and comparison between genders.

DomainsCDUC
Males Femalesp-valueMalesFemalesp-value
Intestinal59.45±13.6742.59±15.320.00257.47±9.9053.38±10.340.149
Systemic26.82±7.6217.41±8.890.003229.00±5.2723.77±6.950.018
Emotional63.64±17.1645.82±21.240.01165.60±13.8755.38±19.140.0625
Social25,91 ± 8,6519.47±9.850.0428.47±8.1125.54±6.960.156
The scatter diagram (Figure 2) was used to verify the relationship between the various aspects and the total score where a higher R² value corresponds to a more accurate adjustment. It can be seen that for the population with IBD, the characteristic that best explained the total IBDQ score was that of intestinal symptoms and the one that explained the least was that of social aspects.
Figure 2 -

Scatter diagram showing the relationship between various aspects and total score.

DISCUSSION

This was a prospective study assessed in a sample of patients with IBD who were followed up in a specialized tertiary hospital in São Paulo, Brazil. We analyzed a number of patients consistent with some studies in the literature on the subject and also the distribution of the two forms of the disease , . Regarding demographic data, we observed an overall mean age similar to the literature , , , ; likewise, the mean duration of disease in this study was similar to the studies surveyed , , for a period of more than 5 years. According to the literature , , , we observed a higher percentage of surgeries among patients with CD (p=0.001); however, with more frequent abdominal surgeries reported in different studies, orificial procedures were notably observed , . Moreover, hospitalizations related to morbidity were also numerous in these patients (p=0.003), which was consistent with the literature , , , , , . Regarding drug therapy, it was noted that among patients with UC, mainly aminosalicylates were used, while biological drugs were mainly used in treating patients with Crohn’s disease, matching the literature surveys , , , . Table 7 compares previous studies with this study and we can observe an acceptable number of patients for the analysis of the impact of IBD on QoL. In addition, it can be seen that the gut and systemic symptom scores of this study are close to those reported by Han et al. and Pallis et al.
Table 7 -

Comparison between IBDQ scores among studies

Domains

Data in this study

(n=56)

Han et al. 13

(n=30)

Boer et al. 7

(n=271)

Pallis et al. 17

(n=135)

Intestinal52.39±14.0554.9±10.437.3±7.758.9±10.7
Systemic23.84±8.5425.3±5.917.0±4.427.7±6.9
Social56.0±19.5429.4±8.120.0±4.729.1±7.5
Emotional24.55±9.0564.1±13.744.9±9.162.4±15.6
Total157.63±46.67173.7±33.1119.1±22.0178.1±36.9
Data in this study (n=56) Han et al. (n=30) Boer et al. (n=271) Pallis et al. (n=135) Although the scores for the social and emotional aspects differ from those found in these publications, it is noticeable that the total IBDQ score of this study falls between the ranges , . Van der Eijk et al. showed that psychological stress, including anxiety, depression, and stressful life events, has a negative impact on the QoL of patients with IBD. In this study, female patients with IBD, CD, and UC had lower IBDQ scores when compared to males (p=0.0005, 0.004, and 0.05, respectively), inferring that they have a greater impairment in QoL, which is consistent with the study by Magalhães et al. who showed that women with CD presented significantly lower IBDQ score than men (p=0.023). However, the results of same study differ from ours in patients with UC, as we also observed a greater impact on QoL in females (p=0.05), whereas in the cited work, we did not observe a significant impact on QoL (p=0.061). It was also observed in the present study that the total IBDQ score is more affected in patients with Crohn’s disease (p=0.022), which is consistent with the literature , ; however, it differs from the studies of some authors which do not show statistical difference , , . As a limitation of the study, one can think of the relatively small number of patients; however, a prospective collection performed by a single researcher in a university health center is another limitation. Moreover, this study emphasizes the necessary appreciation of the QoL in patients with IBD, looking for a better assistance to these patients with chronic disease.

CONCLUSIONS

Patients with Crohn’s disease are more commonly submitted to surgeries and hospitalizations with a greater impairment of QoL - notably in females - among patients with IBD.
  21 in total

Review 1.  The quality of life in patients with Crohn's disease.

Authors:  R D Cohen
Journal:  Aliment Pharmacol Ther       Date:  2002-09       Impact factor: 8.171

2.  Assessment of quality of life of patients with inflammatory bowel disease residing in Southern Brazil.

Authors:  Danielle Cohen; Ceres Maltz Bin; Ana Paula Trussardi Fayh
Journal:  Arq Gastroenterol       Date:  2010 Jul-Sep

3.  Surgery for Intestinal Crohn's Disease: Results of a multidisciplinary approach.

Authors:  Deniz Atasoy; Afag Aghayeva; Erman Aytaç; İlknur Erenler; Aykut Ferhat Çelik; Bilgi Baca; Tayfun Karahasanoğlu; İsmail Hamzaoğlu
Journal:  Turk J Surg       Date:  2018-08-31

4.  The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England.

Authors:  S W Han; E McColl; N Steen; J R Barton; M R Welfare
Journal:  Scand J Gastroenterol       Date:  1998-09       Impact factor: 2.423

5.  Ulcerative colitis and Crohn's disease.

Authors:  Kunj Gohil; Brielle Carramusa
Journal:  P T       Date:  2014-08

6.  The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.

Authors: 
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

7.  Validation of the mainland Chinese version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for ulcerative colitis and Crohn's disease.

Authors:  W H Ren; M Lai; Y Chen; E J Irvine; Y X Zhou
Journal:  Inflamm Bowel Dis       Date:  2007-07       Impact factor: 5.325

8.  Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil.

Authors:  Carlos Roberto Victoria; Ligia Yukie Sassak; Hélio Rubens de Carvalho Nunes
Journal:  Arq Gastroenterol       Date:  2009 Jan-Mar

9.  [Quality of life in patients with inflammatory bowel diseases: translation to Portuguese language and validation of the "Inflammatory Bowel Disease Questionnaire" (IBDQ)].

Authors:  Rose Meire Albuquerque Pontes; Sender Jankiel Miszputen; Olavo Franco Ferreira-Filho; Cláudio Miranda; Marcos Bosi Ferraz
Journal:  Arq Gastroenterol       Date:  2004-10-27

10.  Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece.

Authors:  Athanasios G Pallis; Ioannis G Vlachonikolis; Ioannis A Mouzas
Journal:  BMC Gastroenterol       Date:  2002-01-10       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.